SCHEMBL6449459

SCHEMBL6449459

N#Cc1c(NCc2ccc(C(F)(F)F)cc2)nc(N)nc1-n1cccn1

nearest known ligand 0.52

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
APP P05067 4/20 0.52
ADORA2A P29274 1/20 0.43
HRH4 Q9H3N8 1/20 0.40
USP1 O94782 2/20 0.39
WDR48 Q8TAF3 2/20 0.39
CHUK O15111 1/20 0.39
NLRP3 Q96P20 2/20 0.38
KDM4E B2RXH2 2/20 0.37
PDE2A O00408 1/20 0.37
EPHX2 P34913 1/20 0.36
GHSR Q92847 1/20 0.36
TPH1 P17752 1/20 0.36
EGFR P00533 1/20 0.36
MEN1 O00255 1/20 0.36
ALDH1A1 P00352 1/20 0.36
GAA P10253 1/20 0.36
HPGD P15428 1/20 0.36
HTT P42858 1/20 0.36
KMT2A Q03164 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6443235 0.88 ADORA2A (0.49) APPADORA2ACHUKNLRP3KDM4E
SCHEMBL6446164 0.82 ADORA2A (0.43) APPADORA2ACHUKNLRP3KDM4E
SCHEMBL6442124 0.81 P2RX3 (0.41) APPADORA2ANLRP3KDM4EMEN1
SCHEMBL6443539 0.79 ADORA2A (0.48) APPADORA2ACHUKNLRP3KDM4E
SCHEMBL6440840 0.78 ADORA2A (0.45) ADORA2AHRH4CHUKNLRP3KDM4E
SCHEMBL6443563 0.78 ADORA2A (0.45) ADORA2AHRH4CHUKNLRP3KDM4E
SCHEMBL6441943 0.76 ADORA2A (0.46) APPADORA2ACHUKNLRP3
SCHEMBL6443232 0.75 ADORA2A (0.42) APPADORA2ANLRP3KDM4EMEN1
SCHEMBL6440882 0.75 ADORA2A (0.42) ADORA2ACHUKNLRP3KDM4EEGFR
SCHEMBL6444939 0.75 APP (0.53) APPHRH4CHUKKDM4EEPHX2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1261327-B1 ADENOSINE RECEPTOR MODULATORS HOFFMANN LA ROCHE (CH) 2005-04-27 EP disclosed
CN-1438890-A Adenosine receptor modulators HOFFMANNLA ROCHE AG F (CH) 2003-08-27 CN disclosed
US-6586441-B2 2-Amino-6-benzylsulfanyl-4-thiophen-2-yl-pyridine-3,5-dicarbo -nitrile as an examplary preferred compound; Alzheimer's and Parkinson's diseases; neuroprotectors; schizophrenia, analgesics; anxiolytic agents; respiratory disorders HOFFMAN-LA ROCHE INC. 2003-07-01 US disclosed
EP-1261327-A2 ADENOSINE RECEPTOR MODULATORS F.HOFFMANN-LA ROCHE AG (CH) 2002-12-04 EP disclosed
US-20010027196-A1 Adenosine receptor ligands and their use in the treatment of disease F. HOFFMANN-LA ROCHE AG (CH) 2001-10-04 US disclosed
WO-2001062233-A2 ADENOSINE RECEPTOR MODULATORS F. HOFFMANN LA ROCHE AG (CH) 2001-08-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010027196-A1 Adenosine receptor ligands and their use in the treatment of disease ADORA2A, ADORA2B, ADORA1 APP 477/4885ADORA2A 1/4885HRH4 140/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.